Table 4.
Adjusted SHR estimate for asymptomatic failure and competing events (death or symptomatic failure) using multivariate competing risk regression analysis
| Variable | Multivariate analysis |
|
|---|---|---|
| Adjusted SHR (95% CI) | p-value | |
| Age | 1.033 (1.006–1.062) | 0.02 |
| Sex | ||
| Male | 1.0 | |
| Female | 1.87 (0.719–4.901) | 0.19 |
| Skipped region | ||
| 0 | 1.0 | |
| 1 | 0.861 (0.311–2.388) | 0.77 |
| 2 | 2.149 (0.666–6.926) | 0.2 |
| ≥3 | 1.263 (0.233–6.837) | 0.78 |
| Metastatic region | ||
| Cervical | 1.0 | |
| Cervicothoracic | 0.814 (0.092–7.173) | 0.85 |
| Thoracic | 0.928 (0.188–4.577) | 0.92 |
| Thoracolumbar | 1.263 (0.186–8.578) | 0.81 |
| Lumbar | 1.604 (0.235–10.919) | 0.62 |
| Lumbosacral | 0.419 (0.038–4.576) | 0.47 |
| Primary tumor | ||
| Breast | 1.0 | |
| Lung | 0.142 (0.044–0.458) | 0.001 |
| Prostate | 0.113 (0.020–0.621) | 0.01 |
| Hematological | 0.230 (0.064–0.813) | 0.02 |
| Othersa) | 0.220 (0.065–0.748) | 0.01 |
| SINS | 0.992 (0.861–1.143) | 0.91 |
| Lesion type | ||
| Sclerotic | 1.0 | |
| Lytic | 0.706 (0.228–2.185) | 0.54 |
| Mixed | 0.822 (0.322–2.0999) | 0.68 |
| Instrumented region | ||
| Cervicothoracic | 1.0 | |
| Thoracic | 1.860 (0.522–6.620) | 0.33 |
| Thoracolumbar | 2.697 (0.801–9.080) | 0.10 |
| Lumbar & lumbosacral | 0.878 (0.157–4.897) | 0.88 |
| Construct length | 0.899 (0.696–1.162) | 0.41 |
| ECOG score | ||
| 3–4 (non-ambulatory) | 1.0 | |
| 0–2 (ambulatory) | 0.725 (0.290–1.809) | 0.49 |
Bold type is considered statistically significant.
SHR, subhazard ratio; CI, confidence interval; SINS, spinal instability neoplastic score; ECOG, Eastern Cooperative Oncology Group.
a)
Others include renal malignancies (n=23), hepatocellular carcinoma/gastrointestinal tumors (n=27), ovarian (n=7), cervical (n=9), thyroid (n=7), nasopharyngeal (n=10), and others (n=2).